EGFR and lung carcinoma: To confirm the superior activity of brigatinib against the triple-mutant EGFR, we performed in vivo experiments by administering brigatinib or osimertinib to nude mice into which EGFR-triple-del19 expressing PC9 lung cancer (PC9-triple mutant) cells had been subcutaneously injected.